Skip to main content
. Author manuscript; available in PMC: 2019 May 16.
Published in final edited form as: J Neurochem. 2018 Nov 19;148(1):29–45. doi: 10.1111/jnc.14606

Fig. 4.

Fig. 4

Antagonism of TAAR1 by N-(3-Ethoxyphenyl)-4-(1-pyrrolidinyl)-3-(trifluoromethyl)benzamide (EPPTB) reversed acute effects of methamphetamine (Meth) on suppressing IKv. (a) Sample traces from human fetal astrocytes (from the left to right) at control condition, treated with Meth (20 μM), or with Meth (20 μM) plus EPPTB (25 nM). The vertical dashed lines indicate the time points at which the currents were measured. (b) The I-V curves show that combined treatment of EPPTB and Meth reversed the Meth-induced decrease in IKv (Control vs. Meth and Meth + EPPTB: n = 22/18 vs. 19/12 and 9/4 cells/independent experiments, respectively; Two-way rmANOVA: treatment: F(2,47) = 1.786, p = 1.786; voltage: F(15,705) = 155.7, p < 0.001; interaction: F(30,705) = 2.112, p < 0.001; with Tukey’s post hoc test: Control vs. Meth, *p < 0.05; Control vs. Meth + EPPTB, #p < 0.05; Meth vs. Meth + EPPTB: +,++,+++p < 0.05, 0.01 or 0.001).